SAB

SAB BIO is a clinical-stage biopharmaceutical company working to treat and prevent immune and autoimmune disorders. Founded in 2014 and traded on NASDAQ (SABS) since 2021, SAB BIO's innovative genetic engineering platform produces human, multi-targeted, high-potency immunoglobulins (IgGs), without the need for human donors or convalescent plasma. The science behind the platform originated in 1998, and the company began its first clinical trials in 2017. ... MIAMI, Oct. 31, 2024 (GLOBE NEWSWIRE) -- SAB BIO (Nasdaq: SABS) (the œCompany or œSAB ), a clinical-stage biopharmaceutical company with a novel immunotherapy platform developing a human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression of type 1 diabetes (T1D), today

Also known as: SAB BIO, SAb Biotherapeutics, SAb Biotherapeutics, Inc.

Primary location: Miami Beach United States